News

Wednesday 14th September 2022

Oral and Dental Problems in Scleroderma: New SRUK-Funded Research Aims to Improve Pathways to Oral Care

Exciting new research run by Professor Liz Walker at the University of Hull and the University of Leeds is aiming to improve oral and dental outcomes for people living with scleroderma, by improving pathways to oral care. You can now get involved in the research team’s study by filling out their short survey about your perspectives on dental and oral care in scleroderma. Find the link on this page!

Friday 9th September 2022

Evusheld Survey: New treatment to prevent COVID-19 infection in people with poor immune systems

Do you have scleroderma and have a weakened immune system? Would you like to have your say on whether a treatment which can prevent COVID-19 infection is made available to those who have poor immune responses in response to COVID-19 vaccination? Complete our short survey to inform our response to a NICE consultation on whether this treatment should be authorised for use.

Wednesday 7th September 2022

Helping demystify multi-organ fibrosis: The DEMISTIFI study

Would you like to find out more about a new study that aims to improve how we understand and treat fibrosis?

Tuesday 9th August 2022

The Decode Scleroderma Study

72 people have signed up for this new trial for people living with diffuse scleroderma and now this clinical study, to test a new investigational drug for use in Diffuse Scleroderma, is ready to start.

Monday 1st August 2022

SRUK supports the call on the UK Government to provide Evusheld - a preventative antibody treatment for COVID-19

Evusheld is an antibody treatment designed to prevent patients from contracting COVID-19, and can provide protection for immunocompromised and immunosuppressed people that haven’t mounted a proper response to the vaccine. SRUK is supporting the call for the UK Government to procure and provide Evusheld to patients in the UK. Find out about how you can help on this page.

Friday 15th July 2022

Six Months of STAR – the Symptom Tracking App for Raynaud’s

July marks six months since Scleroderma & Raynaud’s UK launched STAR, the Symptom Tracking App for Raynaud’s, which enables members of the SRUK community to track their Raynaud's attacks and directly contribute to essential scientific research into the condition. Here’s a breakdown of what we’ve learnt so far, thanks to the STAR community!

Wednesday 29th June 2022

Undiagnosed & Untreated: Realities of Systemic Sclerosis in Europe Today

Wednesday 29th June 2022

Creativity Through Scleroderma

Georgina Foster is an Art Historian and has written this piece especially for World Scleroderma Day to celebrate the great artist Paul Klee, who she admires very much and who also had scleroderma.

Tuesday 28th June 2022

‘Olive Ayoub Intermediate to Late-Stage Post-Doctoral Research Fellowship’ Opens for Applications on 29th June

On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.

Friday 24th June 2022

Identifying Scleroderma Patients at Risk of Pulmonary Hypertension - US Study Provides Potential Biomarker for the Condition

A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.